DE69622466T2 - Inaktivierung von Prionen in Bindegewebematerialen - Google Patents
Inaktivierung von Prionen in BindegewebematerialenInfo
- Publication number
- DE69622466T2 DE69622466T2 DE69622466T DE69622466T DE69622466T2 DE 69622466 T2 DE69622466 T2 DE 69622466T2 DE 69622466 T DE69622466 T DE 69622466T DE 69622466 T DE69622466 T DE 69622466T DE 69622466 T2 DE69622466 T2 DE 69622466T2
- Authority
- DE
- Germany
- Prior art keywords
- collagen
- sodium hydroxide
- fibers
- solution
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091000054 Prion Proteins 0.000 title claims abstract description 54
- 102000029797 Prion Human genes 0.000 title claims abstract description 53
- 230000002779 inactivation Effects 0.000 title claims abstract description 31
- 210000002808 connective tissue Anatomy 0.000 title abstract description 27
- 239000000463 material Substances 0.000 title abstract description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 649
- 102000008186 Collagen Human genes 0.000 claims abstract description 291
- 108010035532 Collagen Proteins 0.000 claims abstract description 291
- 229920001436 collagen Polymers 0.000 claims abstract description 290
- 238000011282 treatment Methods 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000012678 infectious agent Substances 0.000 claims abstract description 19
- 239000006193 liquid solution Substances 0.000 claims abstract description 8
- 239000000835 fiber Substances 0.000 claims description 190
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 13
- 230000001524 infective effect Effects 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 103
- 238000002844 melting Methods 0.000 description 49
- 230000008018 melting Effects 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 35
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 35
- 239000000203 mixture Substances 0.000 description 32
- 244000052769 pathogen Species 0.000 description 31
- 238000010790 dilution Methods 0.000 description 29
- 239000012895 dilution Substances 0.000 description 29
- 208000008864 scrapie Diseases 0.000 description 29
- 230000001717 pathogenic effect Effects 0.000 description 26
- 239000000725 suspension Substances 0.000 description 24
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 210000004556 brain Anatomy 0.000 description 22
- 229960004194 lidocaine Drugs 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 241000699800 Cricetinae Species 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000000113 differential scanning calorimetry Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000000415 inactivating effect Effects 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 9
- 238000004448 titration Methods 0.000 description 9
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 8
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 description 6
- 235000019800 disodium phosphate Nutrition 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 108010007288 PrPSc Proteins Proteins 0.000 description 5
- 208000024777 Prion disease Diseases 0.000 description 5
- 238000000429 assembly Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 102100034452 Alternative prion protein Human genes 0.000 description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
- 241000699673 Mesocricetus auratus Species 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003929 acidic solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 102000013373 fibrillar collagen Human genes 0.000 description 3
- 108060002894 fibrillar collagen Proteins 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003505 heat denaturation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000003134 recirculating effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000010544 human prion disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000026841 staggering gait Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical class [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- -1 hair Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000024188 startle response Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Claims (7)
1. Ein Behandlungsverfahren der Solubilisierung von Kollagen,
um Prionen und andere infektiöse Erreger zu inaktivieren,
welches das Inkontaktbringen des solubilisierten Kollagens mit
Natriumhydroxid in einer flüssigen Lösung, wodurch der
Oberflächenbereich der solubilisierten Kollagenmoleküle exponiert
wird, um die Prionen und andere infektiöse Erreger zur
Behandlung zu exponieren, wobei das Natriumhydroxid in der flüssigen
Lösung im Hinblick auf die Konzentration von 0,1 M bis 0,35 M
reicht, für einen Zeitraum, der ausreicht, um die Prionen und
andere infektiöse Erreger zu inaktivieren, bei einer
Temperatur von 25ºC oder weniger umfasst und wobei das Kollagen in
der Lage ist, nach der Inaktivierung stabile Fasern zu bilden.
2. Das Verfahren nach Anspruch 1, wobei der Zeitraum 90
Minuten oder weniger beträgt.
3. Das Verfahren nach Anspruch 1, wobei die Konzentration an
Natriumhydroxid in der flüssigen Lösung von 0,1 M bis 0,25 M
reicht.
4. Das Verfahren nach Anspruch 3, wobei der Zeitraum 100
Minuten oder weniger beträgt.
5. Das Verfahren nach Anspruch 1, wobei die Konzentration an
Natriumhydroxid in der flüssigen Lösung 0,1 M beträgt.
6. Das Verfahren nach Anspruch 3, wobei die Zeitdauer 150
Minuten oder weniger beträgt.
7. Das Verfahren gemäß irgendeinem der vorhergehenden
Ansprüche, wobei das Verfahren wenigstens einen Schutz von 5 log
erzeugt.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/431,950 US5756678A (en) | 1995-05-01 | 1995-05-01 | Prion inactivation in connective tissue materials |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69622466D1 DE69622466D1 (de) | 2002-08-29 |
| DE69622466T2 true DE69622466T2 (de) | 2002-12-05 |
Family
ID=23714124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69622466T Expired - Fee Related DE69622466T2 (de) | 1995-05-01 | 1996-04-04 | Inaktivierung von Prionen in Bindegewebematerialen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5756678A (de) |
| EP (1) | EP0742018B1 (de) |
| JP (1) | JPH08308912A (de) |
| AT (1) | ATE220927T1 (de) |
| CA (1) | CA2172918A1 (de) |
| DE (1) | DE69622466T2 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000504333A (ja) * | 1996-01-29 | 2000-04-11 | ドワロン，シャルル | プリオン―フリーコラーゲン及びコラーゲン―由来生成物、並びに多数の生物医学用途のための移植片；その製造方法 |
| AUPP276098A0 (en) * | 1998-04-01 | 1998-04-30 | Nokuta Pty Ltd | A method for treating gelatine |
| US6437102B1 (en) | 1999-11-24 | 2002-08-20 | Bayer Corporation | Method of separating prions from biological materials |
| IL148202A0 (en) * | 2000-06-20 | 2002-09-12 | Caprion Pharmaceuticals Inc | Copolymers and methods of treating prion-related diseases |
| US20030050276A1 (en) * | 2001-08-15 | 2003-03-13 | Cunanan Crystal M. | Treatment of tissue, instruments and work surfaces to remove infectious agents |
| US6696074B2 (en) | 2000-12-04 | 2004-02-24 | Tei Biosciences, Inc. | Processing fetal or neo-natal tissue to produce a scaffold for tissue engineering |
| US20080268054A1 (en) * | 2000-12-04 | 2008-10-30 | Eugene Bell | Dermal derived human stem cells and compositions and methods thereof |
| US7303907B2 (en) | 2001-01-08 | 2007-12-04 | Health Protection Agency | Degradation and detection of TSE infectivity |
| US7577577B2 (en) * | 2001-01-31 | 2009-08-18 | Dell Products L.P. | Pull to customer order demand fulfillment system and method |
| AUPR293801A0 (en) * | 2001-02-07 | 2001-03-01 | Novapharm Research (Australia) Pty Ltd | Prion disinfection |
| US6933103B1 (en) * | 2001-03-21 | 2005-08-23 | Brennen Medical, Inc. | Biocompatible tissue for therapeutic use and method of making same |
| US6613505B2 (en) | 2001-04-12 | 2003-09-02 | Bioresource International, Inc. | Composition and method for destruction of infetious prion proteins |
| DE60118981D1 (de) | 2001-05-08 | 2006-05-24 | Serologicals Invest Co | Verfahren zur inaktivierung von prionen in lipoproteinen |
| JP2005501814A (ja) * | 2001-05-16 | 2005-01-20 | バイオマリン ファーマシューティカル インコーポレイテッド | ビブリオリシンまたはその改変体を用いるプリオンの破壊 |
| US20020182261A1 (en) * | 2001-05-31 | 2002-12-05 | Jianwu Dai | EB matrix production from fetal tissues and its use for tissue repair |
| JP2005518226A (ja) * | 2001-05-31 | 2005-06-23 | ティーイーアイ バイオサイエンシズ，インコーポレイテッド | 胎児組織由来のｅｂマトリックスの作製及び組織修復のためのその使用 |
| US7803315B2 (en) * | 2001-10-05 | 2010-09-28 | American Sterilizer Company | Decontamination of surfaces contaminated with prion-infected material with gaseous oxidizing agents |
| US7001873B2 (en) * | 2001-10-05 | 2006-02-21 | Steris Inc. | Decontamination of surfaces contaminated with prion-infected material with oxidizing agent-based formulations |
| CN1639575A (zh) * | 2001-10-05 | 2005-07-13 | 斯特里斯公司 | 用于抗朊病毒活性的体外模型 |
| US20030181371A1 (en) * | 2001-12-28 | 2003-09-25 | Angiotech Pharmaceuticals, Inc. | Compositions and methods of using collajolie |
| US7071152B2 (en) * | 2003-05-30 | 2006-07-04 | Steris Inc. | Cleaning and decontamination formula for surfaces contaminated with prion-infected material |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20050283256A1 (en) * | 2004-02-09 | 2005-12-22 | Codman & Shurtleff, Inc. | Collagen device and method of preparing the same |
| US7429241B2 (en) | 2005-09-29 | 2008-09-30 | Codman & Shurtleff, Inc. | Dural graft and method of preparing the same |
| GB0603775D0 (en) * | 2006-02-24 | 2006-04-05 | Health Prot Agency | Infectivity assay |
| AU2009201541B2 (en) * | 2008-04-23 | 2014-12-04 | Integra Lifesciences Corporation | Flowable collagen material for dural closure |
| EP2549947B1 (de) | 2010-03-24 | 2017-12-13 | Covidien LP | Dreidimensionales chirurgisches kombinationsimplantat |
| US8945156B2 (en) | 2010-05-19 | 2015-02-03 | University Of Utah Research Foundation | Tissue fixation |
| US8858577B2 (en) | 2010-05-19 | 2014-10-14 | University Of Utah Research Foundation | Tissue stabilization system |
| US8852214B2 (en) | 2011-02-04 | 2014-10-07 | University Of Utah Research Foundation | System for tissue fixation to bone |
| US11253252B2 (en) | 2012-07-30 | 2022-02-22 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US10390935B2 (en) | 2012-07-30 | 2019-08-27 | Conextions, Inc. | Soft tissue to bone repair devices, systems, and methods |
| US9427309B2 (en) | 2012-07-30 | 2016-08-30 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
| US9629632B2 (en) | 2012-07-30 | 2017-04-25 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
| US11944531B2 (en) | 2012-07-30 | 2024-04-02 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US10219804B2 (en) | 2012-07-30 | 2019-03-05 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US10835241B2 (en) | 2012-07-30 | 2020-11-17 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US11957334B2 (en) | 2012-07-30 | 2024-04-16 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US11583384B2 (en) | 2014-03-12 | 2023-02-21 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US11696822B2 (en) | 2016-09-28 | 2023-07-11 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US11547397B2 (en) | 2017-12-20 | 2023-01-10 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US12102317B2 (en) | 2017-12-20 | 2024-10-01 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| WO2019164853A1 (en) | 2018-02-20 | 2019-08-29 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
| US11602548B1 (en) | 2018-02-26 | 2023-03-14 | Convatec, Inc | Fibrous birth tissue composition and method of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3131130A (en) * | 1961-07-31 | 1964-04-28 | Ethicon Inc | Method of producing soluble collagen |
| US3530037A (en) * | 1967-03-20 | 1970-09-22 | Tomio Nishihara | Method for solubilization of collagen fibers with proteolytic enzymes |
| FR2516927B1 (fr) * | 1981-11-26 | 1986-05-23 | Merieux Fond | Procede de preparation industrielle de materiaux collageniques a partir de tissus placentaires humains, materiaux collageniques humains obtenus, leur application comme biomateriaux |
| FR2715405B1 (fr) * | 1994-01-24 | 1996-04-05 | Imedex | Procédé pour l'élimination des prions dans des collagènes et collagènes ainsi obtenus. |
| US5616689A (en) * | 1994-07-13 | 1997-04-01 | Collagen Corporation | Method of controlling structure stability of collagen fibers produced form solutions or dispersions treated with sodium hydroxide for infectious agent deactivation |
-
1995
- 1995-05-01 US US08/431,950 patent/US5756678A/en not_active Expired - Lifetime
-
1996
- 1996-03-28 CA CA002172918A patent/CA2172918A1/en not_active Abandoned
- 1996-04-04 AT AT96105478T patent/ATE220927T1/de not_active IP Right Cessation
- 1996-04-04 EP EP96105478A patent/EP0742018B1/de not_active Expired - Lifetime
- 1996-04-04 DE DE69622466T patent/DE69622466T2/de not_active Expired - Fee Related
- 1996-04-30 JP JP8109888A patent/JPH08308912A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ATE220927T1 (de) | 2002-08-15 |
| US5756678A (en) | 1998-05-26 |
| EP0742018A2 (de) | 1996-11-13 |
| DE69622466D1 (de) | 2002-08-29 |
| EP0742018A3 (de) | 2000-03-01 |
| EP0742018B1 (de) | 2002-07-24 |
| JPH08308912A (ja) | 1996-11-26 |
| CA2172918A1 (en) | 1996-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69622466T2 (de) | Inaktivierung von Prionen in Bindegewebematerialen | |
| DE69521653T2 (de) | Verfahren zur Kontrolle der Strukturstabilität von Kollagenfasern hergestellt aus Lösungen und Dispersionen, behandelt mit Natriumhydroxid für die Deaktivierung von infektiösen Wirkstoffen | |
| DE69632313T2 (de) | Desorbierbare extrazelluläre matrix für rekonstruktion eines knorpelgewebes | |
| DE68927631T2 (de) | Wässrige Augenlösung und Verfahren zur Konservierung derselben | |
| DE69127020T2 (de) | Milchproteinhydrolysate und Zusammensetzungen zur Verwendung als Haar- und Hautbehandlungsmittel | |
| DE69704929T2 (de) | Prionen-freies kollagen und von kollagen abgeleitete produkte und implantate für verschiedene biomedizinische anwendungen und methoden für ihre herstellung. | |
| DE2646968C2 (de) | ||
| DE69729217T3 (de) | Methode zur chromatographischen entfernung von prionen | |
| AT408191B (de) | Verfahren zur inaktivierung von prionen | |
| DE2827297C2 (de) | Verfahren zum Hitzesterilisieren von Plasmapulver, Serumpulver, Blutkörperchenpulver oder Gesamtblutpulver | |
| DE69429051T2 (de) | Verwendung von Wasser zur Herstellung einer Zubereitung zur Behandlung von Dermatosen bei Haustieren | |
| DE60203599T2 (de) | Methode zur Inaktivierung von TSE | |
| DE1949195A1 (de) | Verfahren zur Herstellung deproteinisierter Bluextrakte mit Heilwirkung | |
| EP2328623B1 (de) | Verfahren zur verringerung der viralen und mikrobiellen belastung feststoffhaltiger aus dem pankreas von tieren gewonnener extrakte | |
| DE69032578T2 (de) | Verfahren zur herstellung und reinigung von einer glykosphingolipidmischung frei von verunreinigungen durch ungewöhnliche viren | |
| AT390560B (de) | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern | |
| DE60109897T2 (de) | Zur inaktivierung von infektiösen proteinen behandelte zusammensetzungen | |
| DE60011567T2 (de) | Behandlung von protein enthaltenden flüssigkeiten | |
| EP0577996B1 (de) | Placentaextrakt und Verfahren zu seiner Herstellung | |
| EP0776212B1 (de) | Verfahren zur herstellung von infektionsfreien pharmazeutischen präparaten und/oder nahrungsmitteln aus infektiösem, insbesondere prionen enthaltendem, material | |
| DE2436905C3 (de) | Sterile, isotonische wäßrige Zubereitung zum Sterilisieren von weichen Kontaktlinsen | |
| Yamane | Kausal-analytische Studien über die Befruchtung des Kanincheneies II. Die Isolierung der auf das Eizytoplasma auflösend wirkenden Substanzen aus den Spermatozoen | |
| DE60032262T2 (de) | Verwendung einer behandlunglösung zur inaktivierung von prionen | |
| DE2420415A1 (de) | Eine mitogenische blutfraktion und verfahren zur herstellung derselben | |
| DE60310240T2 (de) | Entfernung von prionen-infektiosität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |